Similar articles for PMID: 27807070

Year	Number of Results
2006	2
2007	2
2009	1
2010	3
2011	1
2012	4
2013	6
2014	8
2015	15
2016	5
2017	14
2018	17
2019	6
2020	4
2021	3
2024	0

1

Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation.

Isobe K, Kakimoto A, Mikami T, Kaburaki K, Kobayashi H, Yoshizawa T, Makino T, Otsuka H, Sano GO, Sugino K, Sakamoto S, Takai Y, Tochigi N, Iyoda A, Homma S. Isobe K, et al. Cancer Genomics Proteomics. 2016 11-12;13(6):475-482. doi: 10.21873/cgp.20010. Cancer Genomics Proteomics. 2016. PMID: 27807070 Free PMC article.

2

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.

Takeuchi S, Hase T, Shimizu S, Ando M, Hata A, Murakami H, Kawakami T, Nagase K, Yoshimura K, Fujiwara T, Tanimoto A, Nishiyama A, Arai S, Fukuda K, Katakami N, Takahashi T, Hasegawa Y, Ko TK, Ong ST, Yano S. Takeuchi S, et al. Cancer Sci. 2020 Feb;111(2):561-570. doi: 10.1111/cas.14260. Epub 2020 Jan 6. Cancer Sci. 2020. PMID: 31782583 Free PMC article. Clinical Trial.

3

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.

Lee JY, Ku BM, Lim SH, Lee MY, Kim H, Kim M, Kim S, Jung HA, Sun JM, Ahn JS, Park K, Ahn MJ. Lee JY, et al. J Thorac Oncol. 2015 Jun;10(6):903-9. doi: 10.1097/JTO.0000000000000535. J Thorac Oncol. 2015. PMID: 26001141 Free article.

4

Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer.

Tanimoto A, Takeuchi S, Arai S, Fukuda K, Yamada T, Roca X, Ong ST, Yano S. Tanimoto A, et al. Clin Cancer Res. 2017 Jun 15;23(12):3139-3149. doi: 10.1158/1078-0432.CCR-16-2271. Epub 2016 Dec 16. Clin Cancer Res. 2017. PMID: 27986747

5

EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.

Liu S, He Y, Jiang T, Ren S, Zhou F, Zhao C, Li X, Zhang J, Su C, Chen X, Cai W, Gao G, Li W, Wu F, Li J, Zhao J, Hu Q, Zhao M, Zhou C, Hirsch FR. Liu S, et al. Lung Cancer. 2018 Jun;120:82-87. doi: 10.1016/j.lungcan.2018.04.004. Epub 2018 Apr 4. Lung Cancer. 2018. PMID: 29748021

6

Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.

Ariyasu R, Yanagitani N, Tadokoro K, Yamaguchi T, Uchibori K, Kitazono S, Fujita N, Katayama R, Nishio M. Ariyasu R, et al. Cancer Chemother Pharmacol. 2020 Oct;86(4):517-525. doi: 10.1007/s00280-020-04136-7. Epub 2020 Sep 18. Cancer Chemother Pharmacol. 2020. PMID: 32948919

7

The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.

Zhao M, Zhang Y, Cai W, Li J, Zhou F, Cheng N, Ren R, Zhao C, Li X, Ren S, Zhou C, Hirsch FR. Zhao M, et al. Cancer. 2014 Aug 1;120(15):2299-307. doi: 10.1002/cncr.28725. Epub 2014 Apr 15. Cancer. 2014. PMID: 24737648 Free article.

8

Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.

Takeuchi S, Yoshimura K, Fujiwara T, Ando M, Shimizu S, Nagase K, Hasegawa Y, Takahashi T, Katakami N, Inoue A, Yano S. Takeuchi S, et al. J Med Invest. 2017;64(3.4):321-325. doi: 10.2152/jmi.64.321. J Med Invest. 2017. PMID: 28955007 Free article. Clinical Trial.

9

EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP).

Cardona AF, Ordóñez-Reyes C, Ruiz-Patiño A, Garcia-Robledo JE, Barron LZ, Recondo G, Rojas L, Corrales L, Martín C, Barrón F, Sotelo C, Rodríguez J, Ricaurte L, Rolfo C, Ávila J, Mayorga D, Archila P, Otero J, Mas L, Bermudez M, Gamez T, Carranza H, Vargas C, Rosell R, Arrieta O. Cardona AF, et al. JCO Precis Oncol. 2021 Nov;5:839-848. doi: 10.1200/PO.20.00404. JCO Precis Oncol. 2021. PMID: 34994616

10

Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC.

Incharoen P, Charonpongsuntorn C, Saowapa S, Sirachainan E, Dejthevaporn T, Kampreasart K, Trachu N, Muntham D, Reungwetwattana T. Incharoen P, et al. Asian Pac J Cancer Prev. 2019 Dec 1;20(12):3581-3589. doi: 10.31557/APJCP.2019.20.12.3581. Asian Pac J Cancer Prev. 2019. PMID: 31870097 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

83 results

Results by year